PUBLISHER: DelveInsight | PRODUCT CODE: 1047143
PUBLISHER: DelveInsight | PRODUCT CODE: 1047143
DelveInsight's, "Pegfilgrastim- Biosimilar 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pegfilgrastim Understanding
Pegfilgrastim: Overview
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. It is used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Some patients with greater risk factors may develop febrile neutropenia from myelosuppressive therapy and are susceptible to an increased risk of developing infections. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop a longer acting version of the drug. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim.
Pegfilgrastim Biosimilars: Drugs Chapters
This segment of the Pegfilgrastim report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pegfilgrastim Biosimilars: Marketed Drugs
Nyvepria is a biosimilar to Neulasta, is approved by the FDA to help reduce the chance of infection due to a low white blood cell count in people with non-myeloid cancer who receive anti-cancer medicines, like chemotherapy, that can cause fever and low white blood cell count. This condition, known as febrile neutropenia, is a common side effect of many types of chemotherapy and lowers the body's ability to defend itself against infections.
Further product details are provided in the report……..
Pegfilgrastim Biosimilars: Emerging Drugs
PF-06881894 is a potential biosimilar to Neulasta (Pegfilgrastim) which was initially being developed by Hospira pharma and currently is being developed by Pfizer. The drug is currently in registration phase of development for the treatment of Neutropenia.
Further product details are provided in the report……..
Pegfilgrastim: Therapeutic Assessment
This segment of the report provides insights about the different Pegfilgrastim biosimilars segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Pegfilgrastim.
DelveInsight's report covers around 20+ products under different phases of clinical development like
Pegfilgrastim pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pegfilgrastim: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Pegfilgrastim biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pegfilgrastim biosimilar drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products